An International, Randomized, Double-Blinded, Phase III Efficacy Study of XL 184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

5168 - CTO
Cancer - Thyroid

(Minimal Requirements) Please contact us for a full list of criteria.

Confirmed diagnosis of MTC that is measurable or non-measurable per mRECIST.

Patient must be at least 18 years of age or older.

Tiffany Pearce